{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:56:59Z","timestamp":1790582219109,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023674","name":"King Khalid University Deanship of Scientific Research","doi-asserted-by":"publisher","award":["GRP\/122\/44"],"award-info":[{"award-number":["GRP\/122\/44"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.abd.2026.501422","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:13:50Z","timestamp":1786342430000},"page":"501422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-associated eosinophilic fasciitis: a systematic review of reported cases"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-5372","authenticated-orcid":false,"given":"Yahya","family":"Argobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Tobeigei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris I.","family":"Alasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2026.501422_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2026.501422_bib0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.abd.2026.501422_bib0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.abd.2026.501422_bib0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2026.501422_bib0025","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.abd.2026.501422_bib0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.alit.2019.03.001","article-title":"Eosinophilic fasciitis: from pathophysiology to treatment","volume":"68","author":"Ihn","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.abd.2026.501422_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.berh.2012.08.001","article-title":"Eosinophilic fasciitis (Shulman disease)","volume":"26","author":"Lebeaux","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.abd.2026.501422_bib0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2026.501422_bib0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.abd.2026.501422_bib0050","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/ajd.12836","article-title":"Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab","volume":"59","author":"Andr\u00e9s-Lencina","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2026.501422_bib0055","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jtho.2018.09.016","article-title":"An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab","volume":"14","author":"Le Tallec","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.abd.2026.501422_bib0060","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/rheumatology\/kez164","article-title":"Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response","volume":"58","author":"Toussaint","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.abd.2026.501422_bib0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/JIPO.JIPO_8_19","article-title":"Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer","volume":"2","author":"Wissam","year":"2019","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.abd.2026.501422_bib0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.abd.2026.501422_bib0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jdcr.2020.04.010","article-title":"Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression","volume":"6","author":"Bui","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.abd.2026.501422_bib0080","article-title":"Nivolumab-induced eosinophilic fasciitis: a case report","volume":"4","author":"Ollier","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.abd.2026.501422_bib0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jdcr.2020.04.017","article-title":"Eosinophilic fasciitis in association with nivolumab: the importance of eosinophilia","volume":"6","author":"Pab\u00f3n-Cartagena","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.abd.2026.501422_bib0090","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1684\/ejd.2021.4181","article-title":"Nivolumab-induced multiple morphea associated with eosinophilic fasciitis","volume":"31","author":"Lacombe","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2026.501422_bib0095","article-title":"Complete reversibility of pembrolizumab-induced eosinophilic fasciitis without corticosteroids: a case report","volume":"9","author":"Bourcier","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.abd.2026.501422_bib0100","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.932888","article-title":"Drug-associated eosinophilic fasciitis secondary to cemiplimab therapy","volume":"22","author":"Boppana","year":"2021","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.abd.2026.501422_bib0105","doi-asserted-by":"crossref","first-page":"376","DOI":"10.31138\/mjr.32.4.376","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy with pembrolizumab","volume":"32","author":"Zampeli","year":"2021","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.abd.2026.501422_bib0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.36401\/JIPO-21-19","article-title":"Eosinophilic fasciitis with concurrent necrobiotic granulomatous dermatitis related to checkpoint inhibition therapy","volume":"5","author":"Haroon","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.abd.2026.501422_bib0115","article-title":"Case report: eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET\/CT","volume":"9","author":"Amrane","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.abd.2026.501422_bib0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.annder.2023.07.001","article-title":"Nivolumab-induced eosinophilic fasciitis: an unusual immune-related adverse event","volume":"150","author":"Benzaquen","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.abd.2026.501422_bib0125","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.948323","article-title":"Eosinophilic fasciitis in a 78-year-old man following pembrolizumab treatment for bladder cancer","volume":"26","author":"Oke","year":"2025","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.abd.2026.501422_bib0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.revmed.2025.05.004","article-title":"Immune checkpoint inhibitor-related eosinophilic fasciitis: 3 case reports with literature review","volume":"46","author":"Biteau","year":"2025","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.abd.2026.501422_bib0135","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.abd.2026.501422_bib0140","unstructured":"jbi.global [Internet]. Adelaide: JBI; c2026 [cited 2025 Dec 27]. Available from: https:\/\/jbi.global\/critical-appraisal-tools."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626001352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626001352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:26:34Z","timestamp":1790580394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059626001352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0365059626001352"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2026.501422","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-associated eosinophilic fasciitis: a systematic review of reported cases","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2026.501422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501422"}}